Post-earnings recap
Reported
Thu, May 7, 2026
EPS actual
$2.03
EPS est.
$1.89
EPS surprise
+7.69%
1-day move
-1.64%
Gilead Sciences reported better-than-expected earnings per share, but did not provide revenue figures or future guidance. The stock reacted negatively, declining by 1.64%, which may reflect investor concerns over the lack of revenue details and future outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $2.03 | $1.91 | +7.69% |
| Revenue | N/A | $6.9B | N/A |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.
Gilead Sciences, Inc. is a biotechnology company focused on developing innovative medicines for serious diseases, particularly in the fields of HIV, liver diseases, and oncology. With a market cap of $169 billion, Gilead plays a significant role in the healthcare sector, addressing critical health challenges and advancing treatment options.
Last quarter
In Q4 2025, Gilead reported an EPS of $1.86, exceeding expectations by 1.92%. However, the stock dropped 2.93% the following day, indicating market caution despite the earnings beat.
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+9.35%
Avg 1-day reaction
+0.08%
Analysts expect Gilead to report solid earnings this quarter, with a consensus EPS of $1.91 and revenue of $6.9 billion. Investors will be closely watching for any signs of growth in key therapeutic areas.
Bull case
If Gilead exceeds EPS and revenue expectations, it could signal strong demand for its products and a positive outlook for future growth, potentially boosting investor confidence.
Bear case
Conversely, if Gilead misses estimates or provides weak guidance, it could raise concerns about its market position and future profitability, leading to a negative reaction.
Key metrics to watch
EPS
$1.91Earnings per share is a key indicator of profitability and will show how well Gilead is managing costs and generating income.
Revenue
$6.9BTotal revenue reflects the company's sales performance and growth trajectory, which is crucial for investor confidence.
The print will turn on these.
Q1
Will Gilead's EPS exceed the consensus estimate of $1.91?
A beat on EPS would reinforce confidence in Gilead's profitability and growth potential, impacting stock performance.
Q2
What guidance will Gilead provide regarding future revenue growth?
Future revenue guidance will be critical for investor sentiment, as it indicates the company's outlook in a competitive market.
Est. EPS
$3.70
Est. Rev
$3.9B
Impl. Move
±4.7%
Why consensus could be wrong
The Street may underestimate Gilead's potential for revenue growth in emerging markets, where demand for its therapies is increasing.
Supporting evidence
Recent insider selling may indicate a lack of confidence in the near-term performance, which could affect investor sentiment.
Options pricing suggests a larger move than historical averages, indicating heightened uncertainty that may not align with actual performance.
Key risk
If Gilead's revenue growth in emerging markets exceeds expectations, it could challenge the current consensus.
Pre-commit to what would confirm each case.
The market is focused on Gilead's ability to maintain profitability and growth in a competitive biotechnology landscape.
Bull confirmed if
Exceeding an EPS of $1.91 and revenue of $6.9 billion would confirm a strong performance.
Bear confirmed if
Falling short of the consensus EPS and revenue expectations would signal potential challenges ahead.
What the market is pricing for the move.
Implied Move
±4.88%
Historical Avg
±1.3%
The options market is pricing in a significant move around the earnings report, suggesting that traders expect volatility.
Options are pricing ±4.9% while GILD has averaged ±1.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.8%
30d HV
20.9%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$2.2M
15,000 sh
1 insider
Net
$2.2M
Net selling
Most Active Insiders· 2 open-market trades
$2.2M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
92.20%
of float
Insider
0.11%
of float
Holders
3,072
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
121,844,108 sh · $17.9B
9.83%
2.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Gilead beats expectations, history suggests the stock could see a positive reaction, potentially around a 1.3% move upwards.
In line / cautious
If results are in line with expectations but management is cautious, the stock may experience muted movement as investors reassess future growth.
Miss
Should Gilead miss estimates, history indicates a potential drop, with an average reaction of around -0.18% when they beat.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $147.72
12,000 sh
$1.8M
Oct 1, 2026 · @ $148.63
3,000 sh
$445,879.50
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Capital Management LLC
81,091,734 sh · $11.9B
6.54%
0.5%
FMR, LLC
66,870,816 sh · $9.8B
5.39%
-7.0%
State Street Corporation
61,216,552 sh · $9.0B
4.94%
2.3%
Capital World Investors
40,988,975 sh · $6.0B
3.31%
-0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 6, 2026 · disclosed Jun 19, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.